Global Quinolones Market, By Disease Type (Urinary Tract Infection, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections and Others), Pathogen Type (Gram-Positive Pathogen, Gram-Negative Pathogen), Drugs (Lomefloxacin, Gatifloxacin, Norfloxacin, Moxifloxacin, Ciprofloxacin and Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Quinolones Market Analysis and Size
The demand for quinolones is increasing on account of US$ 56.8 billion by 2026. Growing demand for quinolones is also estimated to leadto the growth of the quinolones market share. The rise in incidence of infectious diseases globally acts as one of the primary factors enhancing the growth of quinolones market. Numerous quinolones are currently available for the treatment of animals globally which includes poultry and fish.
Data Bridge Market Research analyses a growth rate in the quinolones market in the forecast period 2023-2030. The expected CAGR of the quinolones market tends to be around 4.5% in the mentioned forecast period. The market value is USD 48.8 billion in 2022, and it would grow up to USD 69.40 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Quinolones Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Urinary Tract Infection, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections and Others), Pathogen Type (Gram-Positive Pathogen, Gram-Negative Pathogen), Drugs (Lomefloxacin, Gatifloxacin, Norfloxacin, Moxifloxacin, Ciprofloxacin and Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Abbvie, Inc (U.S.), Pfizer Inc (U.S.), Viatris Inc. (U.S.), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Zydus Group (India), Bausch Health Companies Inc. (Canada), KYORIN Holdings, Inc (Japan), MerLion Pharmaceuticals GmbH (Germany), WOCKHARDT (India), Johnson & Johnson Private Limited (U.S.), Teva Pharmaceutical Industries Ltd.(Israel) and Sanofi (France)
|
|
Market Opportunities
|
|
Market Definition
A quinolone antibiotic is a broad-spectrum bactericide which has a bicyclic core structure having the chemical 4-quinolone. Quinolones are used to treat several bacterial infections in veterinary and human medicine and animal husbandry. They are classified into five distinct classes, in which one is antibiotics. Quinolones are highly effective against stomach, skin, lungs, sinuses, and urinary tract bacterial infections.
Quinolones Market Dynamics
Drivers
- Increased Awareness About Health Issues
Growing health awareness and increasing disposable income have encouraged people to drift towards healthy products, which will benefit them from the adverse health effects. Rising incidence of multidrug-resistant bacteria, raises public health concerns and also creates opportunities for medication producers. Furthermore, the European Medicines Agency's pharmacovigilance risk assessment committee has advised restricting many antibiotics by mouth, inhalation, or injection because of their long-lasting adverse effects. Thus, this expands the market growth.
Opportunities
- Growing Launch of Products
There has been launch of several products that are helpful for the market growth. For instance, in January 2018, Melinta Therapeutics, Inc. launched Baxdela. Baxdela is an oral fluoroquinolone used to treat adult patients with susceptible bacterial acute bacterial skin and skin structure infections (ABSSSI). Baxdela's introduction offers a new therapy alternative and expands the company's infection therapies space. Furthermore, KYORIN Holdings, Inc. announced that the Japanese Ministry of Health, Labor, and Welfare approved Lasvic (lascufloxacin hydrochloride), in September 2019, indicated as a first-line monotherapy for treating community-acquired respiratory and ENT infections. Lasvic's approval is a major milestone in the company's efforts to protect the increasing danger of antimicrobial resistance and provide patients with suitable treatment alternatives.
Restraints/Challenges
- Adverse Effects of Quinolones
Several side-effects are associated with the use of quinolones, because of which some of the drugs such as Tequin manufactured by Bristol-Myers Squibb have been withdrawn from the market in a very short span after their launch in 2006. As per the United States Food & Drug Administration, Tequin was discontinued because of the adverse reactions in 2.7% of more than 5,000 treated patients. Thus, the adverse effects are restraining the market growth.
This quinolones market market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the quinolones market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Global Quinolones Market Scope
The quinolones market is segmented on the basis of disease type, pathogen type, drugs, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Urinary Tract Infection
- Intra-Abdominal Infections
- Blood Stream Infections
- Clostridium Difficile Infections
- Others
Pathogen Type
- Gram-Positive Pathogen
- Gram-Negative Pathogen
Drugs
- Lomefloxacin
- Gatifloxacin
- Norfloxacin
- Moxifloxacin
- Ciprofloxacin
- Others
Route of Administration
- Oral
- Injectable
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Quinolones Market Regional Analysis/Insights
The quinolones market is analyzed and market size insights and trends are provided by disease type, pathogen type, drugs, route of administration, end users and distribution channel as referenced above.
The major countries covered in the quinolones market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing the highest growth for the quinolones market throughout the forecasted period because of the increasing level of disposable income.
North America dominates the market due to the growing number of R&D activities and increasing healthcare expenditure that will boost the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Quinolones Market Share Analysis
The quinolones market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to quinolones market.
Key players operating in the quinolones market include:
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Abbvie, Inc (U.S.)
- Merck & Co., Inc. (U.S.)
- Pfizer Inc (U.S.)
- Viatris Inc. (U.S.)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Zydus Group (India)
- Bausch Health Companies Inc. (Canada)
- KYORIN Holdings, Inc (Japan)
- MerLion Pharmaceuticals GmbH (Germany)
- WOCKHARDT (India)
- Johnson & Johnson Private Limited (U.S.)
- Teva Pharmaceutical Industries Ltd.( Israel)
- Sanofi (France)
SKU-